Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-Label, Multi Center, Randomized Study of LM-302 Versus Treatment of Physician's Choice (TPC) in Patients With CLDN18.2-Positive, Locally Advanced or Metastatic Gastric(GC) and Gastroesophageal Junction(GEJ) Adenocarcinoma.

NCT06351020 is registered in ClinicalTrials.gov with LaNova Medicines Zhejiang Co., Ltd. as lead sponsor.

NCT NCT06351020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06351020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-Label, Multi Center, Randomized Study of LM-302 Versus Treatment of Physician's Choice (TPC) in Patients With CLDN18.2-Positive, Locally Advanced or Metastatic Gastric(GC) and Gastroesophageal Junction(GEJ) Adenocarcinoma.
Lead sponsor
LaNova Medicines Zhejiang Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 24, 2024
Completion date
December 15, 2026
Enrollment
387 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic gc and gcj adenocarcinoma